ERIS

Eris Lifesciences Share Price

₹1,349.15 +117.25 (9.52%)

05 Feb, 2025 12:20

SIP TrendupStart SIP in ERIS

Start SIP

Performance

  • Low
  • ₹1,230
  • High
  • ₹1,384
  • 52 Week Low
  • ₹809
  • 52 Week High
  • ₹1,594
  • Open Price₹1,230
  • Previous Close₹1,232
  • Volume969,647

Investment Returns

  • Over 1 Month + 3.99%
  • Over 3 Month + 2.4%
  • Over 6 Month + 20.35%
  • Over 1 Year + 51.24%
SIP Lightning

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Invest Now

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 55.8
  • PEG Ratio
  • -3.8
  • Market Cap Cr
  • 18,366
  • P/B Ratio
  • 6.6
  • Average True Range
  • 49.92
  • EPS
  • 24.19
  • Dividend Yield
  • 0
  • MACD Signal
  • -37.6
  • RSI
  • 44.04
  • MFI
  • 37.35

Eris Lifesciences Financials

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,349.15
+ 117.25 (9.52%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹1,246.43
  • 50 Day
  • ₹1,295.38
  • 100 Day
  • ₹1,294.08
  • 200 Day
  • ₹1,214.25

Resistance and Support

1222.62 Pivot Speed
  • R3 1,354.53
  • R2 1,307.47
  • R1 1,269.68
  • S1 1,184.83
  • S2 1,137.77
  • S3 1,099.98

What's your outlook on Eris Lifesciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Ltd. is a leading Indian pharmaceutical company specializing in chronic and sub-chronic therapies. With 70% in-house manufacturing and a pan-India distribution network, Eris generates 86% of its revenue from chronic care, serving over 500,000 chemists nationwide.

Eris Lifesciences has an operating revenue of Rs. 2,495.89 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 31 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-04 Quarterly Results
2024-10-25 Quarterly Results
2024-08-02 Quarterly Results
2024-05-21 Audited Results & Fund Raising
2024-02-13 Quarterly Results
Date Purpose Remarks
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend

Eris Lifesciences F&O

Eris Lifesciences Shareholding Pattern

54.86%
16.52%
0.74%
8.36%
0%
9.29%
10.23%

About Eris Lifesciences

  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • Chairperson & Managing Director
  • Mr. Amit Bakshi
  • ISIN
  • INE406M01024

Similar Stocks to Eris Lifesciences

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,349 As on 05 February, 2025 | 12:06

The Market Cap of Eris Lifesciences is ₹18365.9 Cr As on 05 February, 2025 | 12:06

The P/E ratio of Eris Lifesciences is 55.8 As on 05 February, 2025 | 12:06

The PB ratio of Eris Lifesciences is 6.6 As on 05 February, 2025 | 12:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23